Skip to main content

Advertisement

SpringerLink
Log in

Simultaneous use of Tumor Necrosis Factor, Lipid Profile, and β-hCG As Markers of Severity of Preeclampsia

  • Original Article
  • Published:
The Journal of Obstetrics and Gynecology of India Aims and scope Submit manuscript

Abstract

Objective

Tumor necrosis factor, Lipid Profile, and β-hCG are markers that proved to be changed with preeclampsia. We aim to study their combined use as predictors of the severity of preeclampsia.

Methods

A case–control study was conducted in our University Hospitals on pregnant women complicated by mild or severe PE and healthy normal pregnant women as a control group. Samples of these markers were taken at a gestational age between 28 and 36 weeks.

Results

A total number of 90 pregnant women were selected. The first group was mild PE (17 cases), the second group was severe PE (28 cases), and the third group was normal pregnant women (control group 45 cases). There is a statistically significant positive correlation between β-hCG, triglycerides, Cholesterol, LDL, VLDL, and Tumor necrosis factor. These markers correlate with the severity of PE. HDL demonstrates a statistically significant negative correlation with TNF-α and β-hCG.

Conclusions

There is a strong correlation between the increase of TNF, β-hCG, triglycerides, LDL, and cholesterol in cases of PE. These markers are associated with the severity of PE. These markers can be incorporated into a predictive model for PE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Contini C, Winkler BS, Maass N, et al. Concomitant intrauterine growth restriction alters the lipoprotein profile in preeclampsia. Pregnancy Hypertens. 2019;1(15):154–60.

    Article  Google Scholar 

  2. Lau SY, Guild SJ, Barrett CJ, et al. Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. Am J Reprod Immunol. 2013;70:412–27.

    CAS  PubMed  Google Scholar 

  3. Udenze I, Amadi C, Awolola N, et al. The role of cytokines as inflammatory mediators in preeclampsia. Pan Afr Med J. 2015;20(1):219.

    PubMed  PubMed Central  Google Scholar 

  4. Weel IC, Baergen RN, Romão-Veiga M, et al. Association between placental lesions, cytokines and angiogenic factors in pregnant women with preeclampsia. PLoS ONE. 2016;11(6):e0157584.

    Article  Google Scholar 

  5. Trisnawati E, Nontji W. Tumour necrosis factor-α (TNF-α) serum levels in preeclampsia pregnant women and pregnant women at risk with preeclampsia. Enfermeria Clin. 2020;1(30):27–30.

    Article  Google Scholar 

  6. Jammalamadaga VS, Abraham P. Abnormal lipid metabolism is associated with angiogenic and anti angiogenic factor imbalance in PIH women. Int J Reprod Contracept Obstet Gynecol. 2017;6(9):3984.

    Article  Google Scholar 

  7. Spracklen CN, Smith CJ, Saftlas AF, et al. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. Am J Epidemiol. 2014;180(4):346–58.

    Article  Google Scholar 

  8. Wang Y, Shi D, Chen L. Lipid profile and cytokines in hypertension of pregnancy: a comparison of preeclampsia therapies. J Clin Hypertens. 2018;20(2):394–9.

    Article  CAS  Google Scholar 

  9. Olsen RN, Woelkers D, Dunsmoor-Su R, et al. Abnormal second-trimester serum analytes are more predictive of preterm preeclampsia. Am J Obstet Gynecol. 2012;207(3):228-e1.

    Article  Google Scholar 

  10. Jelliffe-Pawlowski LL, Baer RJ, Currier RJ, et al. Early-onset severe preeclampsia by first trimester pregnancy-associated plasma protein A and total human chorionic gonadotropin. Am J Perinatol. 2015;32(07):703–12.

    PubMed  Google Scholar 

  11. Taher SI, Alalaf SK. Association between serum beta-human chorionic gonadotropin and preeclampsia and its effects on perinatal and maternal outcomes: a case control study. Arch Gynecol Obstet. 2019;299(3):713–8.

    Article  CAS  Google Scholar 

  12. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstetrics and gynecology. 2013 122(5):1122.

  13. Winkler K, Contini C, König B, et al. Treatment of very preterm preeclampsia via heparin-mediated extracorporeal LDL-precipitation (HELP) apheresis: the Freiburg preeclampsia HELP-Apheresis study. Pregnancy Hypertens. 2018;1(12):136–43.

    Article  Google Scholar 

  14. Daskalakis G, Bellos I, Nikolakea M, et al. The role of serum adipokine levels in preeclampsia: a systematic review. Metabolism. 2020;106:154172.

    Article  CAS  Google Scholar 

  15. Barjaktarovic M, Korevaar TI, Jaddoe VW, et al. Human chorionic gonadotropin and risk of pre-eclampsia: prospective population-based cohort study. Ultrasound Obstet Gynecol. 2019;54(4):477–83.

    Article  CAS  Google Scholar 

  16. Tesfay F, Negash M, Alemu J, et al. Role of platelet parameters in early detection and prediction of severity of preeclampsia: A comparative cross-sectional study at Ayder comprehensive specialized and Mekelle general hospitals, Mekelle, Tigray, Ethiopia. PLoS ONE. 2019;14(11):e0225536.

    Article  CAS  Google Scholar 

  17. Kurtoglu E, Avci B, Kokcu A, et al. Serum VEGF and PGF may be significant markers in prediction of severity of preeclampsia. J Matern Fetal Neonatal Med. 2016;29(12):1987–92.

    Article  CAS  Google Scholar 

  18. Kang Q, Li W, Yu N, et al. Predictive role of neutrophil-to-lymphocyte ratio in preeclampsia: a meta-analysis including 3982 patients. Pregnancy Hypertens. 2020;1(20):111–8.

    Article  Google Scholar 

  19. Youssef HM, Marei ES. Association of MicroRNA-210 and MicroRNA-155 with severity of preeclampsia. Pregnancy Hypertens. 2019;1(17):49–53.

    Article  Google Scholar 

  20. Ukah UV, De Silva DA, Payne B, et al. Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: a systematic review. Pregnancy Hypertens. 2018;1(11):115–23.

    Article  Google Scholar 

  21. Panwar M, Kumari A, Arora R, et al. Raised neutrophil lymphocyte ratio and serum beta hCG level in early second trimester of pregnancy as predictors for development and severity of preeclampsia. Drug Discov Ther. 2019;13(1):34–7.

    Article  CAS  Google Scholar 

  22. Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206(1):58-e1.

    Article  Google Scholar 

  23. Duhig K, Seed PT, Placzek A, et al. A prognostic model to guide decision-making on timing of delivery in late preterm pre-eclampsia: the PEACOCK prospective cohort study. Health Technol Assess (Winchester Engl). 2021;25(30):1.

    Article  Google Scholar 

Download references

Funding

The authors declare that no fund.

Author information

Authors and Affiliations

  1. Resident of Obstetrics and Gynecology, Mansoura General Hospital, Mansoura, Egypt

    Reham Elazab (Dr)

  2. Obstetrics and Gynecology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

    Mostafa Alkhiary (Prof), Mohamed Bedairi (Prof) & Alaa Wageh (Dr)

Authors
  1. Reham Elazab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mostafa Alkhiary
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Bedairi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alaa Wageh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alaa Wageh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethical Research Committee of the Obstetrics and Gynecology Department and institutional review board (IRB) in the Faulty of Medicine, (MS/17.11.36).

Informed consent

Written Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Dr. Reham Elazab, Resident of obstetrics and gynecology Mansoura University Hospitals, Fetomatenal subspecialty, Egypt; Prof. Dr. Mostafa Elkhaiary, MD, Professor of obstetrics and gynecology, Mansoura faculty of medicine, Egypt; Prof. Dr. Mohamed Bedairi, MD, Professor of obstetrics and gynecology, Mansoura faculty of medicine, Egypt; Dr. Alaa Wageh, MD, Associate Professor of obstetrics and gynecology, Mansoura faculty of medicine, Egypt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elazab, R., Alkhiary, M., Bedairi, M. et al. Simultaneous use of Tumor Necrosis Factor, Lipid Profile, and β-hCG As Markers of Severity of Preeclampsia. J Obstet Gynecol India 72 (Suppl 1), 83–88 (2022). https://doi.org/10.1007/s13224-021-01556-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13224-021-01556-0

Keywords

Search

Navigation